FIXX News and Press, Homology Medicines Inc. From 09/27/22

SAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently deploying capital in breakthrough science o...

Genetic medicines company Homology Medicines ( NASDAQ: FIXX ) promoted Chief Scientific Officer Albert Seymour to the position of CEO, president and board member. Seymour succeeds Arthur Tzianabos, who has been appointed as chairperson. Source: Press R...

Arthur Tzianabos, Ph.D., Named Chairperson of the Board of Directors BEDFORD, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the promotion of Albert Seymour, Ph.D., to Chief Executive Officer (CEO), Pre...

Homology Medicines press release ( NASDAQ: FIXX ): Q2 GAAP EPS of -$0.51 beats by $0.04 . Revenue of $0.8M (-63.5% Y/Y) misses by $0.31M . For further details see: Homology Medicines GAAP EPS of -$0.51 beats by $0.04, revenue of $0.8M misses by $0.31M

- On Track for Updates on pheEDIT and juMPStart Programs by End of 2022 - - Prioritized Pipeline, Shifting Resources to HMI-103 PKU Gene Editing Trial in Adults While Pausing Enrollment in HMI-102 PKU Gene Therapy Trial Also in Adults - - Received Clearance from ...

- Candidate Showed Ability to Target Central Nervous System and Peripheral Organs Following a Single I.V. Administration in MLD Model, a Key Differentiator from Available Treatments and Product Candidates - - Data Demonstrated Biodistribution to Brain Regions and Multi...

Homology Medicines ( NASDAQ: FIXX ) on Tuesday announced peer-reviewed publication of data on its AAVHSC16 capsid. FIXX stock earlier gained as much as 9.8% to a session high of $2.01 and was last up 3.3% in afternoon trading. According to the data, AAHVSC16 sh...

AAVHSC16 Biodistribution Properties in Preclinical Models Demonstrated Potential for Systemic Delivery of Genetic Medicines to Brain, Heart and Muscle BEDFORD, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announ...

BEDFORD, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following conferences: FASEB’s The Genome Engineering Conference: Cutting-Edge Research and Applicati...

Homology Medicines (NASDAQ:FIXX) on Monday said that the U.S. Food and Drug Administration (FDA) had lifted a clinical hold on the company's pheNIX gene therapy clinical trial with HMI-102 for adults with phenylketonuria (PKU). FIXX stock +2.8% to $2.21 in premarket trading. PKU is ...